|
Brands & Product LinesAbout Us
Molecular Targeting Technologies, Inc. (MTTI)
![]() Our Targets: supported by published data and ongoing Phase I clinical trials: Therapeutics: • EBTATE (Lu-177-EB-DOTA-TATE), a prolonged targeted radiotherapeutics for neuroendocrine tumor (NET). • EBRGD (Lu-177-EBRGD), a prolonged targeted radiotherapeutics for glioblastoma multiforme (GBM), and non-small-cell lung cancer (NSCLC). Diagnostics: • F-18-glucaric acid (a necrosis PET imaging agent) is being developed for early prediction of tumor response to drug treatment. • TDURA (Tc-99m-duramycin), targets cell death in multiple applications including cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome (SIRS) and organ transplant rejection. *See pipeline page |